NTP42 / ATXA Therap - LARVOL DELTA

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: ATXA Therapeutics Limited | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jan 2024

Trial completion • Trial completion date

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: ATXA Therapeutics Limited | Trial completion date: Mar 2024 ➔ Jul 2024

Trial completion date

Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial. (PubMed, Front Pharmacol) - P1 | "These findings support continued clinical development of NTP42:KVA4 for cardiopulmonary or other relevant diseases with unmet needs. Clinical Trial Registration: clinicaltrials.gov, identifier NCT04919863."

Journal • P1 data • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: ATXA Therapeutics Limited

New P1 trial

A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects (ATS 2023) - "Orally administered NTP42:KVA4 was well tolerated, with favorable PK/PD characteristics and evidence of specific TP target engagement. The Phase I trial findings support continued clinical development of NTP42:KVA4 for PAH and other cardiopulmonary diseases with high unmet needs."

Clinical • P1 data • PK/PD data • Cardiovascular • Hypertension • Hypotension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload. (PubMed, Front Cardiovasc Med) - "This study shows that, through antagonism of TP signaling, NTP42:KVA4 attenuates experimental PAH pathophysiology, not only alleviating pulmonary pathologies but also reducing RV remodeling, promoting beneficial hypertrophy, and improving cardiac function. The findings suggest a direct cardioprotective effect for NTP42:KVA4, and its potential to be a disease-modifying therapy in PAH and other cardiac conditions."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertension • Immunology • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases